PMID- 38004077
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20231127
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 59
IP  - 11
DP  - 2023 Nov 17
TI  - In Vitro Assessment of Anti-Adipogenic and Anti-Inflammatory Properties of Black 
      Cumin (Nigella sativa L.) Seeds Extract on 3T3-L1 Adipocytes and Raw264.7 
      Macrophages.
LID - 10.3390/medicina59112028 [doi]
LID - 2028
AB  - Background and Objectives: This study evaluated the in vitro anti-adipogenic and 
      anti-inflammatory properties of black cumin (Nigella sativa L.) seed extract (BCS 
      extract) as a potential candidate for developing herbal formulations targeting 
      metabolic disorders. Materials and Methods: We evaluated the BCS extract by 
      assessing its 2,2-diphenyl-1-picrohydrazyl (DPPH) radical scavenging activity, 
      levels of prostaglandin E(2) (PGE(2)) and nitric oxide (NO), and mRNA expression 
      levels of key pro-inflammatory mediators. We also quantified the phosphorylation 
      of nuclear factor kappa light chain enhancer of activated B cells (NF-kappaB) and 
      mitogen-activated protein kinases (MAPK) signaling molecules. To assess 
      anti-adipogenic effects, we used differentiated 3T3-L1 cells and BCS extract in 
      doses from 10 to 100 mug/mL. We also determined mRNA levels of key adipogenic 
      genes, including peroxisome proliferator-activated receptor gamma (PPARgamma), 
      CCAAT/enhancer binding protein alpha (C/BEPalpha), adipocyte protein 2 (aP2), lipoprotein 
      lipase (LPL), fatty acid synthase (FAS), and sterol-regulated element-binding 
      protein 1c (SREBP-1c) using real-time quantitative polymerase chain reaction 
      (qPCR). Results: This study showed a concentration-dependent DPPH radical 
      scavenging activity and no toxicity at concentrations up to 30 mug/mL in Raw264.7 
      cells. BCS extract showed an IC(50) of 328.77 +/- 20.52 mug/mL. Notably, 
      pre-treatment with BCS extract (30 mug/mL) significantly enhanced cell viability 
      in lipopolysaccharide (LPS)-treated Raw264.7 cells. BCS extract treatment 
      effectively inhibited LPS-induced production of PGE(2) and NO, as well as the 
      expression of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha 
      (TNF-alpha), cyclooxygenase-2 (COX-2), inducible NO synthase (iNOS), interleukin 
      (IL)-1beta and IL-6, possibly by limiting the phosphorylation of p38, p65, 
      inhibitory kappaBalpha (I-kappaBalpha), and c-Jun N-terminal kinase (JNK). It also significantly 
      attenuated lipid accumulation and key adipogenic genes in 3T3-L1 cells. 
      Conclusions: This study highlights the in vitro anti-adipogenic and 
      anti-inflammatory potential of BCS extract, underscoring its potential as a 
      promising candidate for managing metabolic disorders.
FAU - Bashir, Khawaja Muhammad Imran
AU  - Bashir KMI
AUID- ORCID: 0000-0002-6830-2588
AD  - Department of Seafood Science and Technology, The Institute of Marine Industry, 
      Gyeongsang National University, Tongyeong 53064, Republic of Korea.
AD  - German Engineering Research and Development Center for Life Science Technologies 
      in Medicine and Environment, Busan 46742, Republic of Korea.
FAU - Kim, Jong-Kyu
AU  - Kim JK
AD  - AriBnC Ltd., Yongin 16985, Republic of Korea.
FAU - Chun, Yoon-Seok
AU  - Chun YS
AD  - AriBnC Ltd., Yongin 16985, Republic of Korea.
FAU - Choi, Jae-Suk
AU  - Choi JS
AUID- ORCID: 0000-0002-8151-6054
AD  - Department of Seafood Science and Technology, The Institute of Marine Industry, 
      Gyeongsang National University, Tongyeong 53064, Republic of Korea.
FAU - Ku, Sae-Kwang
AU  - Ku SK
AUID- ORCID: 0000-0003-1269-3804
AD  - Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany 
      University, Gyeongsan 38610, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20231117
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Plant Extracts)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (RNA, Messenger)
RN  - 31C4KY9ESH (Nitric Oxide)
SB  - IM
MH  - Humans
MH  - Animals
MH  - Mice
MH  - *Nigella sativa/metabolism
MH  - 3T3-L1 Cells
MH  - Lipopolysaccharides/metabolism/pharmacology
MH  - Plant Extracts/pharmacology/therapeutic use/chemistry
MH  - Macrophages
MH  - Anti-Inflammatory Agents/pharmacology/therapeutic use
MH  - Adipocytes
MH  - Seeds
MH  - RNA, Messenger/metabolism
MH  - *Metabolic Diseases/metabolism
MH  - Nitric Oxide/metabolism
PMC - PMC10673321
OTO - NOTNLM
OT  - 3T3-L1 cells
OT  - Raw264.7 cells
OT  - adipogenic differentiation
OT  - oil red O
OT  - pro-inflammatory mediators
COIS- J.-K.K. and Y.-S.C. are employed at AriBnC Ltd., and in this research, they only 
      contributed to the preparation and analysis of raw materials to a limited extent. 
      The authors declare no conflict of interest.
EDAT- 2023/11/25 12:42
MHDA- 2023/11/27 12:42
PMCR- 2023/11/17
CRDT- 2023/11/25 01:20
PHST- 2023/10/02 00:00 [received]
PHST- 2023/11/13 00:00 [revised]
PHST- 2023/11/15 00:00 [accepted]
PHST- 2023/11/27 12:42 [medline]
PHST- 2023/11/25 12:42 [pubmed]
PHST- 2023/11/25 01:20 [entrez]
PHST- 2023/11/17 00:00 [pmc-release]
AID - medicina59112028 [pii]
AID - medicina-59-02028 [pii]
AID - 10.3390/medicina59112028 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2023 Nov 17;59(11):2028. doi: 10.3390/medicina59112028.